ESTRO 2025 - Abstract Book

S1601

Clinical – Mixed sites & palliation

ESTRO 2025

characteristics, overall survival (OS), local control (LC), toxicity, prescribed dose and details of SBRT technique were analyzed.

Results: A total of 42 patients with a median age of 65.2 years (range: 16-81 years) were included. The majority of included studies were case reports (N=14, 77,8%), followed by case series (N=2, 11.1%) and retrospective studies (N=2, 11.1%; Table 1 ). Treatment targets were primary cardiac tumors in 10 cases (23.8%) and cardiac metastases in 30 cases (76.2%). Median OS after SBRT was 6 months (range: 1-6 months). At the time of publication, 11 patients (26.2%) were not alive – of which 7 (16.7%) died due to distant progression. A total of 4 (9.5%) local recurrences were reported at a median 5.2 months after SBRT. The median dose to the PTV was 35 Gy (range: 20-60 Gy) with a median of 3 fractions (range: 1-12 fractions) and a median single dose of 8 Gy (range: 5-25 Gy). MRgRT was utilized in 13 cases (31%). 6 patients (14.3%) showed CTCAE Grade 2 toxicity (mild esophagitis: N=4; and moderate dyspnea: N=2). Regarding possible cardiotoxicity, 4 (9.5%) showed transient mild chest pain symptoms (CTCAE Grade I). No CTCAE toxicities ≥ Grade 3 were reported.